View ValuationCosmo 향후 성장Future 기준 점검 5/6Cosmo (는) 각각 연간 41.8% 및 26.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 41.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 13.9% 로 예상됩니다.핵심 정보41.8%이익 성장률41.76%EPS 성장률Pharmaceuticals 이익 성장23.7%매출 성장률26.6%향후 자기자본이익률13.90%애널리스트 커버리지Good마지막 업데이트14 May 2026최근 향후 성장 업데이트Breakeven Date Change • Dec 31Forecast breakeven date pushed back to 2022The 2 analysts covering Cosmo Pharmaceuticals previously expected the company to break even in 2021. New consensus forecast suggests the company will make a profit of €3.95m in 2022. Average annual earnings growth of 37% is required to achieve expected profit on schedule.Breakeven Date Change • Sep 23Forecast to breakeven in 2021The 3 analysts covering Cosmo Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €5.22m in 2021. Earnings growth of 59% is required to achieve expected profit on schedule.Breakeven Date Change • Aug 04Forecast breakeven moved forward to 2021The 3 analysts covering Cosmo Pharmaceuticals previously expected the company to break even in 2022. New consensus forecast suggests the company will make a profit of €6.00m in 2021. Earnings growth of 60% is required to achieve expected profit on schedule.공시 • Mar 27Cosmo Pharmaceuticals N.V. Provides Earnings Guidance for the Year 2021Cosmo Pharmaceuticals N.V. provided earnings guidance for the year 2021. For the year, the company’s revenues to be in the range of €60 million to €64 million and operating profit to be in the range of €3 million to €5 million.모든 업데이트 보기Recent updatesBoard Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Executive VP of Corporate Governance, Chief Sustainability Officer & Executive Director Niall Donnelly was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Mar 14Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026, at 12:00 W. Europe Standard Time.공시 • Feb 04Cosmo Pharmaceuticals N.V. announced that it has received funding from Capital Research and Management CompanyCosmo Pharmaceuticals N.V announced that it has completed a private placement with a single institutional investor and issued 937,086 treasury shares representing 5.3% of the company's outstanding shares on February 3, 2026. The transaction included participation from Small cap World Fund of the Capital Group.공시 • Jan 09+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2025 Final Results on Mar 09, 2026Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2025 final results on Mar 09, 2026공시 • Apr 30Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025.공시 • Apr 01Cosmo Pharmaceuticals N.V. Appoints Federico Sommariva as Chief Legal CounselCosmo Pharmaceuticals N.V. announced the appointment of Federico Sommariva as Chief Legal Counsel. Federico reports to the CEO and is member of the management team. Federico Sommariva has many years of legal and management experience in the Lifesciences industry. Since June 2013, he has worked for Gilead Sciences based in Milan (Italy), with increasing responsibilities. Most recently, he acted as Director and Global Legal Business Partner Oncology. He also served for 1.5 years as interim Head of Legal and Compliance for Gilead Sciences Romania. Federico studied law at the University of Milan and started his professional career as Legal Counsel Secondee at H&M in Rome (Italy).공시 • Feb 11Cosmo Pharmaceuticals N.V. Announces the Appointment of Andrea Cherubini as Chief AI OfficerCosmo Pharmaceuticals N.V. announced the appointment of Andrea Cherubini as Chief AI Officer effective immediately. This important decision reflects Cosmo's commitment to integrating Artificial Intelligence as a core strategic pillar in its future growth and innovation roadmap. Andrea will report to the CEO and will be member of the executive leadership team. Andrea has been pivotal in the development and commercialization of Cosmo's GI GeniusT. As Senior Vice President - Science, AI, and Data, he was leading the development of innovative AI solutions for the Cosmo Intelligent Medical Devices division since 2018. His extensive clinical expertise, data-driven approach, and leadership in AI have already transformed patient outcomes, showcasing the real-world impact of AI in medical applications. AI as a Strategic Growth Driver In his new role as Chief AI Officer, Andrea will spearhead the expansion of AI beyond endoscopy, embedding it across Cosmo's entire portfolio to accelerate innovation, enhance efficiencies, and unlock new value for both patients and shareholders. This includes, among others: Gastroenterology Pipeline - Advancing AI applications in drug development, particularly for Bile Acid Diarrhea (BAD), to drive precision medicine and predictive analytics in GI disorders. Dermatology Pipeline - Leveraging AI to optimize clinical trial design, patient selection, and personalized treatment pathways for Breezula and other dermatological innovations. AI-Enabled Drug Discovery & Development - Expanding AI's role in R&D, regulatory strategies, and digital health applications, reinforcing Cosmo's position as a leader in AI-driven healthcare solutions. At the same time, Andrea will continue to play a critical role in shaping Cosmo's Intelligent Medical Devices division's AI roadmap, reinforcing GI GeniusT as the leading real-time AI platform in endoscopy.공시 • Jan 21+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Results on Mar 06, 2025Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2024 results on Mar 06, 2025공시 • Jan 08Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Final Results on Mar 20, 2025Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2024 final results at 12:00 PM, Central European Standard Time on Mar 20, 2025공시 • Oct 12Cosmo Pharmaceuticals N.V. Announces Chief Financial Officer ChangesCosmo Pharmaceuticals N.V. announced the appointment of Svetlana Sigalova as its new Chief Financial Officer, effective November 11, 2024. Svetlana will succeed Niall Donnelly, who has served as CFO since 2016. Svetlana Sigalova brings a wealth of expertise from her time at Moderna, where she served as Vice President of Commercial Finance and led the financial operations for over $6 billion in global sales. Her proven ability to develop financial infrastructure and planning systems was pivotal in Moderna's rapid growth during the pandemic. Prior to Moderna, Svetlana held senior finance leadership positions at Alexion Pharmaceuticals and Vertex Pharmaceuticals, where she managed multibillion-dollar revenue streams, built high-performance finance teams, and drove operational efficiency. Niall will transition to a strategic new role as EVP - Corporate Governance & Chief Sustainability Officer, where he will report to CEO and play a key part in strengthening Cosmo's corporate governance framework and driving the Company's mission to advance environmental, social, and governance (ESG) initiatives. With a focus on achieving carbon footprint reduction and sustainable business practices, Niall's leadership will ensure Cosmo continues to build a strong and responsible organization with a robust governance structure that aligns with the Company's long-term growth and value creation. He will also remain an executive member of the Board of Directors of Cosmo.Reported Earnings • Jul 29First half 2024 earnings released: EPS: €4.72 (vs €0.092 in 1H 2023)First half 2024 results: EPS: €4.72 (up from €0.092 in 1H 2023). Revenue: €136.2m (up 212% from 1H 2023). Net income: €76.0m (up €74.5m from 1H 2023). Profit margin: 56% (up from 3.4% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.New Risk • Jul 28New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 3.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 3.3% per year for the foreseeable future. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.Upcoming Dividend • Jul 03Upcoming dividend of €2.00 per shareEligible shareholders must have bought the stock before 10 July 2024. Payment date: 12 July 2024. The company is not currently making a profit and its cash payout ratio is 92%. Trailing yield: 2.7%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (1.2%).공시 • Apr 28Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024Cosmo Pharmaceuticals N.V. announced the appointment of Giovanni Di Napoli as its new Chief Executive Officer, along with changes to its Board of Directors, at the upcoming Annual General Meeting (AGM) on 24 May 2024. At the same time, it will be proposed at the AGM to appoint longstanding Cosmo CEO Alessandro Della Cha as the new Chairman of Cosmo. Alessandro joined Cosmo in 2006 as member of the Board of Directors and was appointed as CEO of the Company in 2014. Giovanni is an accomplished leader with an excellent track record and joins Cosmo from Medtronic where he held various leadership positions since 2008. Until recently, Giovanni was President of Medtronic's Endoscopy Operating Unit located in Santa Clara, California. In this position, he and his team were responsible for one of the most innovative and fast-growing portfolios in the endoscopy market, which included technologies such as Endoflip, Pillcam, and GI Genius. From July 2017 to November 2020, he was Vice President and General Manager GIH - Gastrointestinal and Hepatology and was Vice President Sales U.S. - GI Solutions from February 2015 to July 2017. From April 2012 to February 2015, he was Director of Sales Marketing for Western Europe. Previously, Giovanni held various leadership positions at Johnson Johnson Medical (2001- 2010). Giovanni has an MBA from the Universita Bocconi, Milan, Italy.New Risk • Mar 24New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 21% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Dividend per share is over 28x earnings per share. Cash payout ratio: 175% Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.2% net profit margin).공시 • Mar 22Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2023 Final Results on Apr 30, 2024Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2023 final results on Apr 30, 2024Reported Earnings • Mar 22Full year 2023 earnings released: EPS: €0.071 (vs €1.05 in FY 2022)Full year 2023 results: EPS: €0.071 (down from €1.05 in FY 2022). Revenue: €96.7m (down 5.3% from FY 2022). Net income: €1.15m (down 93% from FY 2022). Profit margin: 1.2% (down from 17% in FY 2022). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.공시 • Feb 15Cosmo Pharmaceuticals N.V. to Report First Half, 2024 Results on Jul 25, 2024Cosmo Pharmaceuticals N.V. announced that they will report first half, 2024 results on Jul 25, 2024Valuation Update With 7 Day Price Move • Dec 12Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €51.00, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 18x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 30% over the past three years.공시 • Dec 06+ 1 more updateCosmo Pharmaceuticals N.V., Annual General Meeting, May 24, 2024Cosmo Pharmaceuticals N.V., Annual General Meeting, May 24, 2024.Reported Earnings • Jul 28First half 2023 earnings released: EPS: €0.092 (vs €0.48 in 1H 2022)First half 2023 results: EPS: €0.092 (down from €0.48 in 1H 2022). Revenue: €43.7m (up 5.2% from 1H 2022). Net income: €1.49m (down 81% from 1H 2022). Profit margin: 3.4% (down from 19% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Upcoming Dividend • May 24Upcoming dividend of €1.05 per share at 2.0% yieldEligible shareholders must have bought the stock before 31 May 2023. Payment date: 02 June 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.0%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (2.5%).Reported Earnings • Mar 24Full year 2022 earnings released: EPS: €1.05 (vs €1.29 in FY 2021)Full year 2022 results: EPS: €1.05 (down from €1.29 in FY 2021). Revenue: €102.1m (up 57% from FY 2021). Net income: €17.2m (down 21% from FY 2021). Profit margin: 17% (down from 33% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.공시 • Dec 20+ 2 more updatesCosmo Pharmaceuticals N.V., Annual General Meeting, May 26, 2023Cosmo Pharmaceuticals N.V., Annual General Meeting, May 26, 2023.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. No independent directors (7 non-independent directors). Non-Executive Director Kevin Donovan was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Jul 29First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (up €5.74m from 1H 2021). Profit margin: (up from net loss in 1H 2021). The move to profitability was driven by lower expenses. Over the next year, revenue is forecast to grow 50%, compared to a 8.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. No independent directors (7 non-independent directors). Non-Executive Director Kevin Donovan was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Breakeven Date Change • Dec 31Forecast breakeven date pushed back to 2022The 2 analysts covering Cosmo Pharmaceuticals previously expected the company to break even in 2021. New consensus forecast suggests the company will make a profit of €3.95m in 2022. Average annual earnings growth of 37% is required to achieve expected profit on schedule.Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Breakeven Date Change • Sep 23Forecast to breakeven in 2021The 3 analysts covering Cosmo Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €5.22m in 2021. Earnings growth of 59% is required to achieve expected profit on schedule.Breakeven Date Change • Aug 04Forecast breakeven moved forward to 2021The 3 analysts covering Cosmo Pharmaceuticals previously expected the company to break even in 2022. New consensus forecast suggests the company will make a profit of €6.00m in 2021. Earnings growth of 60% is required to achieve expected profit on schedule.Reported Earnings • Aug 02First half 2021 earnings released: €0.40 loss per share (vs €0.21 loss in 1H 2020)The company reported a soft first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: €28.4m (up 9.8% from 1H 2020). Net loss: €5.74m (loss widened 90% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.Executive Departure • Jun 04Non-Executive Director Hans Tanner has left the companyOn the 29th of May, Hans Tanner's tenure as Non-Executive Director ended. We don't have any record of a personal shareholding under Hans' name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 4.83 years.공시 • Mar 27Cosmo Pharmaceuticals N.V. Provides Earnings Guidance for the Year 2021Cosmo Pharmaceuticals N.V. provided earnings guidance for the year 2021. For the year, the company’s revenues to be in the range of €60 million to €64 million and operating profit to be in the range of €3 million to €5 million.Reported Earnings • Mar 27Full year 2020 earnings released: €0.55 loss per share (vs €1.67 loss in FY 2019)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: €60.9m (down 2.5% from FY 2019). Net loss: €7.90m (loss narrowed 68% from FY 2019). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Mar 06New 90-day low: €71.50The company is down 7.0% from its price of €76.60 on 04 December 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period.공시 • Feb 18Cosmo Pharmaceuticals Strengthens Partnership with RedHill Biopharma with Manufacturing Agreement for Movantik, RHB-204 and OpaganibCosmo Pharmaceuticals NV announced an agreement with RedHill Biopharma Ltd. to manufacture three key products; Movantik® (RedHill's selling product in the U.S.), RHB-204 (currently in a Phase III U.S. study as a stand-alone first-line treatment for pulmonary nontuberculous mycobacteria (NTM) disease) and opaganib (a new, orally-administered, chemical entity currently in a global Phase II/III study for treatment of COVID-19 pneumonia). These agreements provide secure high-quality manufacturing capacity for all three products. Movantik is the leading prescribed oral peripherally acting mu-opioid receptor antagonist (PAMORA) in the U.S. specifically designed to treat opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain1. OIC is the most common and debilitating gastrointestinal adverse effect associated with opioid therapy, estimated to affect between 40-80% of the millions of patients taking chronic opioid therapy each year. RHB-204 is RedHill's investigational proprietary, fixed-dose oral capsule containing a combination of clarithromycin, rifabutin, and clofazimine, developed as a stand-alone first-line treatment for pulmonary NTM disease caused by Mycobacterium avium Complex (MAC). Although rare, the incidence and prevalence of pulmonary NTM disease are increasing in many areas of the world. There were an estimated 110,000 pulmonary NTM disease patients in the U.S. in 2017, with U.S. market potential estimated at over USD 500 million. RHB-204 has received FDA Fast Track, Orphan Drug and QIDP designations aimed at accelerating development and FDA review and extending U.S. market exclusivity to a potential total of 12 years, to be granted at the time of FDA approval. Opaganib is being evaluated by RedHill as a treatment for COVID-19 pneumonia in a global Phase II/III study and has demonstrated positive safety and efficacy top-line data from a U.S. Phase II study. Opaganib, a new chemical entity, is a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor with demonstrated dual anti-inflammatory and antiviral activity that targets a host cell component of viral replication, potentially minimizing the likelihood of viral resistance. It has also shown anticancer activity and has the potential to target multiple oncology, viral, inflammatory, and gastrointestinal indications. Opaganib received Orphan Drug designation from the U.S. FDA for the treatment of cholangiocarcinoma and is also being evaluated in a Phase IIa study in advanced cholangiocarcinoma and in a Phase II study in prostate cancer.공시 • Feb 06Alfasigma Spa Enters into Licensing Agreement to Distribute Lumeblue™ in the Eu with Cosmo PharmaceuticalsAlfasigma Spa announced that it has finalized a licensing agreement to distribute Lumeblue™ in the EU with Cosmo Pharmaceuticals. Lumeble™ was recently approved by EMA for the detection of lesions during colonoscopy. Cosmo will receive a €4 million upfront payment from Alfasigma, plus double-digit royalties and commercial milestones. Cosmo will be the exclusive supplier of Lumeblue™.Is New 90 Day High Low • Feb 06New 90-day high: €80.00The company is up 8.0% from its price of €74.20 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 15% over the same period.공시 • Feb 05Cosmo Pharmaceuticals NV Announces License of Lumeblue EU Rights to AlfasigmaCosmo Pharmaceuticals NV announced that it has licensed the EU rights (plus Switzerland, UK, EEA countries, Russia and Mexico) for Lumeblue™ to Alfasigma S.p.A. Lumeblue™ is Cosmo's recently EMA approved drug for the detection of lesions during colonoscopy.공시 • Jan 29RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo PharmaceuticalsRedHill Biopharma Ltd. announced a manufacturing agreement with Cosmo Pharmaceuticals NV to further expand manufacturing capacity for opaganib (Yeliva®, ABC294640)1, to address prospective demand subsequent to potential global emergency use authorizations. The global Phase 2/3 study of opaganib in severe COVID-19 pneumonia (NCT04467840) is ongoing, with patients enrolled in more than 30 sites in multiple countries. An interim independent Data and Safety Monitoring Board (DSMB) futility analysis will be conducted in the coming days, evaluating data from the first 135 subjects that have reached the primary endpoint. The study has previously undergone two unblinded independent DSMB safety data reviews, with unanimous recommendations to continue the study. Preliminary data from a non-powered U.S. Phase 2 study of 40 hospitalized patients recently showed that opaganib was safe and demonstrated greater improvement in reducing oxygen requirement by end of treatment on Day 14 across key primary and secondary efficacy outcomes, correlating with clinical improvement as defined by the World Health Organization (WHO) ordinal scale.공시 • Jan 12Cosmo Pharmaceuticals N.V Announces Successful Outcome of Rifamycin 600Mg Phase II trial in IBS-DCosmo Pharmaceuticals N.V announced the successful outcome of its Phase II Proof of Concept (POC) clinical trial of Rifamycin-MMX 600mg in Irritable Bowel Syndrome with Diarrhea (IBS-D). The drug tested is different from Aemcolo®/Relafalk®, which is already approved for Traveler's Diarrhea: while it shares the same active ingredient (Rifamycin SV) and MMX technology, it contains a higher dose of API (600mg) and different release features. The trial investigated the efficacy and safety of two doses of Rifamycin SV-MMX 600mg against placebo after a 2-week course of treatment followed by a 3 months follow-up. The primary endpoint was the proportion of subjects who achieved success, defined as an adequate relief of both abdominal pain and diarrhea at the end of the first week of treatment (at least 30% decrease in pain score and at least 50% reduction in the number of days per week with diarrhea). Other endpoints included reduction in bloating, improved stool consistency, decreased sense of urgency, and improvement in quality of life as assessed through the IBS QoL questionnaire. The trial was conducted in 25 sites located in 4 countries in Western Europe and recruited 279 patients in the ITT ("Intention to treat") population. The trial was very successful notwithstanding the decision by Cosmo to reduce the envisaged sample size by 20% due to COVID-19 restrictions. Results show the achievement of statistical significance in all the study populations (ITT, FAS, m-FAS and PP) for the composite primary endpoint (substantial pain and diarrhea decrease) [OR 3.26 (1.39 - 7.67); p-value 0.0066] and for most secondary endpoints such as adequate relief of IBS-related symptoms [OR 2.18 (1.12 - 4.26); p-value 0.0227 ] and IBS-related bloating at the end of treatment period [OR 2.13 (1.11 - 4.07); p-value 0.0223].공시 • Dec 19+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2020 Results on Mar 26, 2021Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2020 results on Mar 26, 2021공시 • Dec 15Cosmo Pharmaceuticals Announces Amendment of Its Investment Agreement with AcaciaCosmo Pharmaceuticals N.V. announced that, on 14 December 2020, Acacia Pharma Group plc and Cosmo entered into an amendment agreement (the "Amendment Agreement") being an amendment to the Investment Agreement between the parties dated 10 January 2020, pursuant to which Acacia and Cosmo agreed that, in exchange for Cosmo prioritising the packaging and labelling production run for BYFAVOTM for supply in the US, Acacia shall make the EUR 5 million payment due on the first commercial sale of BYFAVOTM in advance of the first commercial sale of BYFAVOTM and by no later than 31 December 2020. Acacia Pharma is preparing to launch BYFAVOTM in the US in the coming weeks. Payment will be settled by the Company issuing new ordinary shares in the share capital of the Company (the "New Ordinary Shares") to Cosmo, at an issue price of EUR 2.38 each (being the 15-day volume weighted average price of the Company's shares prior to the date of the Amendment Agreement). Listing and admission to trading of the New Ordinary Shares on Euronext Brussels remains, in accordance with the Investment Agreement, conditional upon the necessary regulatory approvals being obtained from the FCA and the Belgian FSMA.이익 및 매출 성장 예측DB:C43 - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028216569784412/31/2027170418470512/31/2026120101216612/31/2025104-4-18-12N/A9/30/2025143282431N/A6/30/2025182606774N/A3/31/202522597112118N/A12/31/2024267133157162N/A9/30/202422696127130N/A6/30/2024185599897N/A3/31/2024139245860N/A12/31/202393-111823N/A9/30/20239902129N/A6/30/2023104112436N/A3/31/2023103142535N/A12/31/2022102172633N/A9/30/202290261724N/A6/30/20227835816N/A3/31/20227228614N/A12/31/20216522413N/A9/30/2021646816N/A6/30/202163-111219N/A3/31/202162-9816N/A12/31/202061-8513N/A9/30/202064-7-16N/A6/30/202067-7-80N/A3/31/202065-16-22-9N/A12/31/201962-24-36-19N/A9/30/201956-28N/A-17N/A6/30/201950-31N/A-15N/A3/31/201958-24N/A-12N/A12/31/201866-18N/A-10N/A9/30/201869-20N/A-10N/A6/30/201873-23N/A-11N/A3/31/201870-28N/A-10N/A12/31/201768-32N/A-9N/A9/30/201768-18N/A-6N/A6/30/201769-4N/A-2N/A3/31/2017698N/A10N/A12/31/20166819N/A22N/A9/30/20167018N/A18N/A6/30/20167216N/A14N/A3/31/201666132N/A-13N/A12/31/201561248N/A-39N/A9/30/201560241N/A-13N/A6/30/201559234N/A13N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: C43 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(1.9%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: C43 (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: C43 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: C43 의 수익(연간 26.6%)이 German 시장(연간 6.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: C43 의 수익(연간 26.6%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: C43의 자본 수익률은 3년 후 13.9%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 09:09종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cosmo N.V.는 11명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Estelle BétriseyBerenbergLaura HindleyBerenbergKerry HolfordBerenberg8명의 분석가 더 보기
Breakeven Date Change • Dec 31Forecast breakeven date pushed back to 2022The 2 analysts covering Cosmo Pharmaceuticals previously expected the company to break even in 2021. New consensus forecast suggests the company will make a profit of €3.95m in 2022. Average annual earnings growth of 37% is required to achieve expected profit on schedule.
Breakeven Date Change • Sep 23Forecast to breakeven in 2021The 3 analysts covering Cosmo Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €5.22m in 2021. Earnings growth of 59% is required to achieve expected profit on schedule.
Breakeven Date Change • Aug 04Forecast breakeven moved forward to 2021The 3 analysts covering Cosmo Pharmaceuticals previously expected the company to break even in 2022. New consensus forecast suggests the company will make a profit of €6.00m in 2021. Earnings growth of 60% is required to achieve expected profit on schedule.
공시 • Mar 27Cosmo Pharmaceuticals N.V. Provides Earnings Guidance for the Year 2021Cosmo Pharmaceuticals N.V. provided earnings guidance for the year 2021. For the year, the company’s revenues to be in the range of €60 million to €64 million and operating profit to be in the range of €3 million to €5 million.
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Executive VP of Corporate Governance, Chief Sustainability Officer & Executive Director Niall Donnelly was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Mar 14Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026, at 12:00 W. Europe Standard Time.
공시 • Feb 04Cosmo Pharmaceuticals N.V. announced that it has received funding from Capital Research and Management CompanyCosmo Pharmaceuticals N.V announced that it has completed a private placement with a single institutional investor and issued 937,086 treasury shares representing 5.3% of the company's outstanding shares on February 3, 2026. The transaction included participation from Small cap World Fund of the Capital Group.
공시 • Jan 09+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2025 Final Results on Mar 09, 2026Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2025 final results on Mar 09, 2026
공시 • Apr 30Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025.
공시 • Apr 01Cosmo Pharmaceuticals N.V. Appoints Federico Sommariva as Chief Legal CounselCosmo Pharmaceuticals N.V. announced the appointment of Federico Sommariva as Chief Legal Counsel. Federico reports to the CEO and is member of the management team. Federico Sommariva has many years of legal and management experience in the Lifesciences industry. Since June 2013, he has worked for Gilead Sciences based in Milan (Italy), with increasing responsibilities. Most recently, he acted as Director and Global Legal Business Partner Oncology. He also served for 1.5 years as interim Head of Legal and Compliance for Gilead Sciences Romania. Federico studied law at the University of Milan and started his professional career as Legal Counsel Secondee at H&M in Rome (Italy).
공시 • Feb 11Cosmo Pharmaceuticals N.V. Announces the Appointment of Andrea Cherubini as Chief AI OfficerCosmo Pharmaceuticals N.V. announced the appointment of Andrea Cherubini as Chief AI Officer effective immediately. This important decision reflects Cosmo's commitment to integrating Artificial Intelligence as a core strategic pillar in its future growth and innovation roadmap. Andrea will report to the CEO and will be member of the executive leadership team. Andrea has been pivotal in the development and commercialization of Cosmo's GI GeniusT. As Senior Vice President - Science, AI, and Data, he was leading the development of innovative AI solutions for the Cosmo Intelligent Medical Devices division since 2018. His extensive clinical expertise, data-driven approach, and leadership in AI have already transformed patient outcomes, showcasing the real-world impact of AI in medical applications. AI as a Strategic Growth Driver In his new role as Chief AI Officer, Andrea will spearhead the expansion of AI beyond endoscopy, embedding it across Cosmo's entire portfolio to accelerate innovation, enhance efficiencies, and unlock new value for both patients and shareholders. This includes, among others: Gastroenterology Pipeline - Advancing AI applications in drug development, particularly for Bile Acid Diarrhea (BAD), to drive precision medicine and predictive analytics in GI disorders. Dermatology Pipeline - Leveraging AI to optimize clinical trial design, patient selection, and personalized treatment pathways for Breezula and other dermatological innovations. AI-Enabled Drug Discovery & Development - Expanding AI's role in R&D, regulatory strategies, and digital health applications, reinforcing Cosmo's position as a leader in AI-driven healthcare solutions. At the same time, Andrea will continue to play a critical role in shaping Cosmo's Intelligent Medical Devices division's AI roadmap, reinforcing GI GeniusT as the leading real-time AI platform in endoscopy.
공시 • Jan 21+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Results on Mar 06, 2025Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2024 results on Mar 06, 2025
공시 • Jan 08Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Final Results on Mar 20, 2025Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2024 final results at 12:00 PM, Central European Standard Time on Mar 20, 2025
공시 • Oct 12Cosmo Pharmaceuticals N.V. Announces Chief Financial Officer ChangesCosmo Pharmaceuticals N.V. announced the appointment of Svetlana Sigalova as its new Chief Financial Officer, effective November 11, 2024. Svetlana will succeed Niall Donnelly, who has served as CFO since 2016. Svetlana Sigalova brings a wealth of expertise from her time at Moderna, where she served as Vice President of Commercial Finance and led the financial operations for over $6 billion in global sales. Her proven ability to develop financial infrastructure and planning systems was pivotal in Moderna's rapid growth during the pandemic. Prior to Moderna, Svetlana held senior finance leadership positions at Alexion Pharmaceuticals and Vertex Pharmaceuticals, where she managed multibillion-dollar revenue streams, built high-performance finance teams, and drove operational efficiency. Niall will transition to a strategic new role as EVP - Corporate Governance & Chief Sustainability Officer, where he will report to CEO and play a key part in strengthening Cosmo's corporate governance framework and driving the Company's mission to advance environmental, social, and governance (ESG) initiatives. With a focus on achieving carbon footprint reduction and sustainable business practices, Niall's leadership will ensure Cosmo continues to build a strong and responsible organization with a robust governance structure that aligns with the Company's long-term growth and value creation. He will also remain an executive member of the Board of Directors of Cosmo.
Reported Earnings • Jul 29First half 2024 earnings released: EPS: €4.72 (vs €0.092 in 1H 2023)First half 2024 results: EPS: €4.72 (up from €0.092 in 1H 2023). Revenue: €136.2m (up 212% from 1H 2023). Net income: €76.0m (up €74.5m from 1H 2023). Profit margin: 56% (up from 3.4% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
New Risk • Jul 28New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 3.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 3.3% per year for the foreseeable future. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
Upcoming Dividend • Jul 03Upcoming dividend of €2.00 per shareEligible shareholders must have bought the stock before 10 July 2024. Payment date: 12 July 2024. The company is not currently making a profit and its cash payout ratio is 92%. Trailing yield: 2.7%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (1.2%).
공시 • Apr 28Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024Cosmo Pharmaceuticals N.V. announced the appointment of Giovanni Di Napoli as its new Chief Executive Officer, along with changes to its Board of Directors, at the upcoming Annual General Meeting (AGM) on 24 May 2024. At the same time, it will be proposed at the AGM to appoint longstanding Cosmo CEO Alessandro Della Cha as the new Chairman of Cosmo. Alessandro joined Cosmo in 2006 as member of the Board of Directors and was appointed as CEO of the Company in 2014. Giovanni is an accomplished leader with an excellent track record and joins Cosmo from Medtronic where he held various leadership positions since 2008. Until recently, Giovanni was President of Medtronic's Endoscopy Operating Unit located in Santa Clara, California. In this position, he and his team were responsible for one of the most innovative and fast-growing portfolios in the endoscopy market, which included technologies such as Endoflip, Pillcam, and GI Genius. From July 2017 to November 2020, he was Vice President and General Manager GIH - Gastrointestinal and Hepatology and was Vice President Sales U.S. - GI Solutions from February 2015 to July 2017. From April 2012 to February 2015, he was Director of Sales Marketing for Western Europe. Previously, Giovanni held various leadership positions at Johnson Johnson Medical (2001- 2010). Giovanni has an MBA from the Universita Bocconi, Milan, Italy.
New Risk • Mar 24New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 21% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Dividend per share is over 28x earnings per share. Cash payout ratio: 175% Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.2% net profit margin).
공시 • Mar 22Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2023 Final Results on Apr 30, 2024Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2023 final results on Apr 30, 2024
Reported Earnings • Mar 22Full year 2023 earnings released: EPS: €0.071 (vs €1.05 in FY 2022)Full year 2023 results: EPS: €0.071 (down from €1.05 in FY 2022). Revenue: €96.7m (down 5.3% from FY 2022). Net income: €1.15m (down 93% from FY 2022). Profit margin: 1.2% (down from 17% in FY 2022). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
공시 • Feb 15Cosmo Pharmaceuticals N.V. to Report First Half, 2024 Results on Jul 25, 2024Cosmo Pharmaceuticals N.V. announced that they will report first half, 2024 results on Jul 25, 2024
Valuation Update With 7 Day Price Move • Dec 12Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €51.00, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 18x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 30% over the past three years.
공시 • Dec 06+ 1 more updateCosmo Pharmaceuticals N.V., Annual General Meeting, May 24, 2024Cosmo Pharmaceuticals N.V., Annual General Meeting, May 24, 2024.
Reported Earnings • Jul 28First half 2023 earnings released: EPS: €0.092 (vs €0.48 in 1H 2022)First half 2023 results: EPS: €0.092 (down from €0.48 in 1H 2022). Revenue: €43.7m (up 5.2% from 1H 2022). Net income: €1.49m (down 81% from 1H 2022). Profit margin: 3.4% (down from 19% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Upcoming Dividend • May 24Upcoming dividend of €1.05 per share at 2.0% yieldEligible shareholders must have bought the stock before 31 May 2023. Payment date: 02 June 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.0%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (2.5%).
Reported Earnings • Mar 24Full year 2022 earnings released: EPS: €1.05 (vs €1.29 in FY 2021)Full year 2022 results: EPS: €1.05 (down from €1.29 in FY 2021). Revenue: €102.1m (up 57% from FY 2021). Net income: €17.2m (down 21% from FY 2021). Profit margin: 17% (down from 33% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
공시 • Dec 20+ 2 more updatesCosmo Pharmaceuticals N.V., Annual General Meeting, May 26, 2023Cosmo Pharmaceuticals N.V., Annual General Meeting, May 26, 2023.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. No independent directors (7 non-independent directors). Non-Executive Director Kevin Donovan was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Jul 29First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (up €5.74m from 1H 2021). Profit margin: (up from net loss in 1H 2021). The move to profitability was driven by lower expenses. Over the next year, revenue is forecast to grow 50%, compared to a 8.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. No independent directors (7 non-independent directors). Non-Executive Director Kevin Donovan was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Breakeven Date Change • Dec 31Forecast breakeven date pushed back to 2022The 2 analysts covering Cosmo Pharmaceuticals previously expected the company to break even in 2021. New consensus forecast suggests the company will make a profit of €3.95m in 2022. Average annual earnings growth of 37% is required to achieve expected profit on schedule.
Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Breakeven Date Change • Sep 23Forecast to breakeven in 2021The 3 analysts covering Cosmo Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €5.22m in 2021. Earnings growth of 59% is required to achieve expected profit on schedule.
Breakeven Date Change • Aug 04Forecast breakeven moved forward to 2021The 3 analysts covering Cosmo Pharmaceuticals previously expected the company to break even in 2022. New consensus forecast suggests the company will make a profit of €6.00m in 2021. Earnings growth of 60% is required to achieve expected profit on schedule.
Reported Earnings • Aug 02First half 2021 earnings released: €0.40 loss per share (vs €0.21 loss in 1H 2020)The company reported a soft first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: €28.4m (up 9.8% from 1H 2020). Net loss: €5.74m (loss widened 90% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
Executive Departure • Jun 04Non-Executive Director Hans Tanner has left the companyOn the 29th of May, Hans Tanner's tenure as Non-Executive Director ended. We don't have any record of a personal shareholding under Hans' name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 4.83 years.
공시 • Mar 27Cosmo Pharmaceuticals N.V. Provides Earnings Guidance for the Year 2021Cosmo Pharmaceuticals N.V. provided earnings guidance for the year 2021. For the year, the company’s revenues to be in the range of €60 million to €64 million and operating profit to be in the range of €3 million to €5 million.
Reported Earnings • Mar 27Full year 2020 earnings released: €0.55 loss per share (vs €1.67 loss in FY 2019)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: €60.9m (down 2.5% from FY 2019). Net loss: €7.90m (loss narrowed 68% from FY 2019). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Mar 06New 90-day low: €71.50The company is down 7.0% from its price of €76.60 on 04 December 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period.
공시 • Feb 18Cosmo Pharmaceuticals Strengthens Partnership with RedHill Biopharma with Manufacturing Agreement for Movantik, RHB-204 and OpaganibCosmo Pharmaceuticals NV announced an agreement with RedHill Biopharma Ltd. to manufacture three key products; Movantik® (RedHill's selling product in the U.S.), RHB-204 (currently in a Phase III U.S. study as a stand-alone first-line treatment for pulmonary nontuberculous mycobacteria (NTM) disease) and opaganib (a new, orally-administered, chemical entity currently in a global Phase II/III study for treatment of COVID-19 pneumonia). These agreements provide secure high-quality manufacturing capacity for all three products. Movantik is the leading prescribed oral peripherally acting mu-opioid receptor antagonist (PAMORA) in the U.S. specifically designed to treat opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain1. OIC is the most common and debilitating gastrointestinal adverse effect associated with opioid therapy, estimated to affect between 40-80% of the millions of patients taking chronic opioid therapy each year. RHB-204 is RedHill's investigational proprietary, fixed-dose oral capsule containing a combination of clarithromycin, rifabutin, and clofazimine, developed as a stand-alone first-line treatment for pulmonary NTM disease caused by Mycobacterium avium Complex (MAC). Although rare, the incidence and prevalence of pulmonary NTM disease are increasing in many areas of the world. There were an estimated 110,000 pulmonary NTM disease patients in the U.S. in 2017, with U.S. market potential estimated at over USD 500 million. RHB-204 has received FDA Fast Track, Orphan Drug and QIDP designations aimed at accelerating development and FDA review and extending U.S. market exclusivity to a potential total of 12 years, to be granted at the time of FDA approval. Opaganib is being evaluated by RedHill as a treatment for COVID-19 pneumonia in a global Phase II/III study and has demonstrated positive safety and efficacy top-line data from a U.S. Phase II study. Opaganib, a new chemical entity, is a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor with demonstrated dual anti-inflammatory and antiviral activity that targets a host cell component of viral replication, potentially minimizing the likelihood of viral resistance. It has also shown anticancer activity and has the potential to target multiple oncology, viral, inflammatory, and gastrointestinal indications. Opaganib received Orphan Drug designation from the U.S. FDA for the treatment of cholangiocarcinoma and is also being evaluated in a Phase IIa study in advanced cholangiocarcinoma and in a Phase II study in prostate cancer.
공시 • Feb 06Alfasigma Spa Enters into Licensing Agreement to Distribute Lumeblue™ in the Eu with Cosmo PharmaceuticalsAlfasigma Spa announced that it has finalized a licensing agreement to distribute Lumeblue™ in the EU with Cosmo Pharmaceuticals. Lumeble™ was recently approved by EMA for the detection of lesions during colonoscopy. Cosmo will receive a €4 million upfront payment from Alfasigma, plus double-digit royalties and commercial milestones. Cosmo will be the exclusive supplier of Lumeblue™.
Is New 90 Day High Low • Feb 06New 90-day high: €80.00The company is up 8.0% from its price of €74.20 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 15% over the same period.
공시 • Feb 05Cosmo Pharmaceuticals NV Announces License of Lumeblue EU Rights to AlfasigmaCosmo Pharmaceuticals NV announced that it has licensed the EU rights (plus Switzerland, UK, EEA countries, Russia and Mexico) for Lumeblue™ to Alfasigma S.p.A. Lumeblue™ is Cosmo's recently EMA approved drug for the detection of lesions during colonoscopy.
공시 • Jan 29RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo PharmaceuticalsRedHill Biopharma Ltd. announced a manufacturing agreement with Cosmo Pharmaceuticals NV to further expand manufacturing capacity for opaganib (Yeliva®, ABC294640)1, to address prospective demand subsequent to potential global emergency use authorizations. The global Phase 2/3 study of opaganib in severe COVID-19 pneumonia (NCT04467840) is ongoing, with patients enrolled in more than 30 sites in multiple countries. An interim independent Data and Safety Monitoring Board (DSMB) futility analysis will be conducted in the coming days, evaluating data from the first 135 subjects that have reached the primary endpoint. The study has previously undergone two unblinded independent DSMB safety data reviews, with unanimous recommendations to continue the study. Preliminary data from a non-powered U.S. Phase 2 study of 40 hospitalized patients recently showed that opaganib was safe and demonstrated greater improvement in reducing oxygen requirement by end of treatment on Day 14 across key primary and secondary efficacy outcomes, correlating with clinical improvement as defined by the World Health Organization (WHO) ordinal scale.
공시 • Jan 12Cosmo Pharmaceuticals N.V Announces Successful Outcome of Rifamycin 600Mg Phase II trial in IBS-DCosmo Pharmaceuticals N.V announced the successful outcome of its Phase II Proof of Concept (POC) clinical trial of Rifamycin-MMX 600mg in Irritable Bowel Syndrome with Diarrhea (IBS-D). The drug tested is different from Aemcolo®/Relafalk®, which is already approved for Traveler's Diarrhea: while it shares the same active ingredient (Rifamycin SV) and MMX technology, it contains a higher dose of API (600mg) and different release features. The trial investigated the efficacy and safety of two doses of Rifamycin SV-MMX 600mg against placebo after a 2-week course of treatment followed by a 3 months follow-up. The primary endpoint was the proportion of subjects who achieved success, defined as an adequate relief of both abdominal pain and diarrhea at the end of the first week of treatment (at least 30% decrease in pain score and at least 50% reduction in the number of days per week with diarrhea). Other endpoints included reduction in bloating, improved stool consistency, decreased sense of urgency, and improvement in quality of life as assessed through the IBS QoL questionnaire. The trial was conducted in 25 sites located in 4 countries in Western Europe and recruited 279 patients in the ITT ("Intention to treat") population. The trial was very successful notwithstanding the decision by Cosmo to reduce the envisaged sample size by 20% due to COVID-19 restrictions. Results show the achievement of statistical significance in all the study populations (ITT, FAS, m-FAS and PP) for the composite primary endpoint (substantial pain and diarrhea decrease) [OR 3.26 (1.39 - 7.67); p-value 0.0066] and for most secondary endpoints such as adequate relief of IBS-related symptoms [OR 2.18 (1.12 - 4.26); p-value 0.0227 ] and IBS-related bloating at the end of treatment period [OR 2.13 (1.11 - 4.07); p-value 0.0223].
공시 • Dec 19+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2020 Results on Mar 26, 2021Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2020 results on Mar 26, 2021
공시 • Dec 15Cosmo Pharmaceuticals Announces Amendment of Its Investment Agreement with AcaciaCosmo Pharmaceuticals N.V. announced that, on 14 December 2020, Acacia Pharma Group plc and Cosmo entered into an amendment agreement (the "Amendment Agreement") being an amendment to the Investment Agreement between the parties dated 10 January 2020, pursuant to which Acacia and Cosmo agreed that, in exchange for Cosmo prioritising the packaging and labelling production run for BYFAVOTM for supply in the US, Acacia shall make the EUR 5 million payment due on the first commercial sale of BYFAVOTM in advance of the first commercial sale of BYFAVOTM and by no later than 31 December 2020. Acacia Pharma is preparing to launch BYFAVOTM in the US in the coming weeks. Payment will be settled by the Company issuing new ordinary shares in the share capital of the Company (the "New Ordinary Shares") to Cosmo, at an issue price of EUR 2.38 each (being the 15-day volume weighted average price of the Company's shares prior to the date of the Amendment Agreement). Listing and admission to trading of the New Ordinary Shares on Euronext Brussels remains, in accordance with the Investment Agreement, conditional upon the necessary regulatory approvals being obtained from the FCA and the Belgian FSMA.